Your session is about to expire
← Back to Search
Bevacizumab + Chemoimmunotherapy + Atezolizumab for Small Cell Lung Cancer with Liver Metastases(BELIEVE Trial)
BELIEVE Trial Summary
This trial aims to find out if adding bevacizumab to atezolizumab and chemotherapy can help patients with ES-SCLC and liver metastases live longer without cancer progression.
- Small Cell Lung Cancer
- Liver Metastases
BELIEVE Trial Eligibility Criteria
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
BELIEVE Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2015 Phase 4 trial • 45 Patients • NCT02036424
Awards & Highlights
BELIEVE Trial Design
Find a Location
Who is running the clinical trial?
- Your high blood pressure is not well managed.You had a hole or opening in your stomach or throat in the past 6 months before starting the study.You have visible signs of disease in your body that can be measured according to a specific standard.You have not received any previous treatment for ES-SCLC. However, if you received treatment for limited-stage SCLC, it must have been with the intention of curing the cancer and you must have completed treatment at least six months prior to being diagnosed with ES-SCLC.You have taken medication that weakens your immune system in the last two weeks, or you may need to take such medication during the study.You are able to understand and sign the consent form, and you can follow the study requirements.You have been diagnosed with small cell lung cancer that has spread to your brain, confirmed by medical tests.You have never had bleeding in your brain or spinal cord.You did not receive radiation therapy to the brain or underwent brain surgery within a certain time period before starting the study treatment.You previously had a specific type of lung cancer with a certain gene mutation, and it has now transformed into a different type that has spread to your liver. You have not received chemotherapy or immunotherapy for this type of cancer before.You have a medical condition that can be measured using a standard criteria called RECIST v1.1.The cancer has only spread to the brain in certain areas, but not to the brain stem or other critical parts of the brain.You can take low doses of corticosteroids or anticonvulsants, but the dose should not change during the study.You are currently using or planning to use traditional herbal medicines.You have had a transplant of stem cells or a solid organ from another person in the past.You have a severe, unhealed wound, open sore, or a broken bone that hasn't been treated.You have any other medical condition, physical finding or lab result that might prevent you from safely taking the experimental drug or could make it difficult to interpret the results of the trial.You cannot receive live, weakened vaccines starting four weeks before beginning the study treatment, while receiving atezolizumab, and for five months after the last dose of atezolizumab.You have or had a condition that affects your immune system or autoimmune disease, where your immune system attacks your own body.
- Group 1: Experimental Treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any positions open for patients in this study?
"No, this particular study is not presently looking for participants. The clinicaltrials.gov website indicates that the study was first posted on February 1st 2023 and last updated on October 18th 2022. There are 2377 other trials active recruiting patients at the moment though."
Has the FDA sanctioned this experimental procedure?
"There is some data supporting the safety of this experimental treatment, but none yet for efficacy. We gave it a score of 2."
Share this study with friends